DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates

pedro cahn DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
Pedro Cahn

REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

This entry was posted in Medicine and tagged , , , , , , , , , , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>